Life Science Industry Research and News

  • Products for Cell and Tissue Culture

    LRM001

    Human LR3 IGF1
    Human LR3 Insulin-like Growth Factor 1 (IGF1) is an 83 amino acid analog of human IGF1 comprising the complete human IGF1 sequence with the substitution of an Arg for the Glu at position 3 (hence R3), and a 13 amino acid extension peptide at the N-terminus. Recombinant LR3 IGF1 has been developed specifically for supplementation of mammalian cell culture to support the survival and proliferation of cells. It is engineered to have a higher biological potency than native IGF1 or IGF2 and has several advantages over recombinant insulin, potency being among them. Published research has shown that supplementation of cell cultures with LR3 IGF1 at a much lower concentration results in equivalent or better productivity than supplementation with standard concentrations of insulin. LR3 IGF1 is better able to stimulate the Type I IGF Receptor and thus induce a higher level of activation of intracellular signaling molecules which are responsible for promoting cell survival by inhibition of apoptosis. A new formulation of this analog of IGF1 is lyophilized from a solution in PBS, allowing it to be directly dissolved in water or media.

    LRU100 Recombinant Human LR3 IGF1 100 µg 
    LRM001 Recombinant Human LR3 IGF1 1.0 mg 
    LRM010 Recombinant Human LR3 IGF1 10 mg

    Human Erythropoietin
    Erythropoietin (EPO) is a glycoprotein hormone that controls red blood cell production. It is a cytokine for erythrocyte precursors in the bone marrow. It is produced by the peritubular capillary endothelial cells in the kidney, and is the hormone that regulates red blood cell production. Recombinant Human Erythropoietin (EPO) is a glycosylated polypeptide chain containing 165 amino acids. It is a recombinant protein produced in mammalian cells for use in cell and tissue culture applications.

    CRE600A Recombinant Human EPO 500 IU 
    CRE600B Recombinant Human EPO 2000 IU 
    CRE600C Recombinant Human EPO 150k IU

    Bulk quantities of these products are available, please inquire.

  • CD14 and LBP Products

    CD14 and LBP: ELISA kits, recombinant proteins, monoclonal and polyclonal antibodies

    1454632_613049982084934_928820193_n

    CD14:
    CD14 is the 53-kD glycophosphatidylinositol (GPI)-linked glycoprotein and functions as high affinity endotoxin (LPS) receptor on the surface of monocytes, macrophages and granulocytes as well as brain cells. Together with TLR4 and a lymphocytic antigen (MD2) CD14 is the lipopolysaccharide (LPS)-Receptor and mediates innate immune response to bacterial lipoproteins. In the presence of LPS, CD14-expression can be amplified by TNF-alpha and IL-1 beta. CD14 is present in a soluble form in human serum, urine and other body fluids which is directly secreted or derived from protease-dependent shedding of the membrane bound molecule. Soluble CD14 (sCD14) competes with membrane bound CD14 (mCD14) for LPS binding and is able to neutralize LPS-induced responses in vitro and in vivo and mediates the LPS-induced activation of non-CD14-expressing endothelial, epithelial and smooth-muscle cells.

    CD14 Reagents

    CKH114  Human sCD14 ELISA Kit

    CKM034  Mouse sCD14 ELISA Kit

    CDM150  Mouse Anti-Human CD14 Clone B-A8 Azide Free mAb

    CMC000  Mouse Anti-Human CD14 Clone biG 10 mAb

    CMC001  Mouse Anti-Human CD14 Clone biG 13 multispecies mAb

    CMC005  Mouse Anti-Mouse CD14 Clone biG 53 mAb

    CRCC01  Recombinant Human CD14

    CRCC03  Recombinant Mouse CD14


     

    LBP:
    LBP (Lipopolysaccharide binding protein) is a 58-kD acute phase glycoprotein, binds to the lipid A portion of Lipopolysaccharide (LPS) with high affinity and catalyzed the CD14 and TLR4 dependent cellular activation by LPS. LBP interacted with CD14, TLR2, TLR4 und the co-receptor MD-2. LBP is involved in the acute-phase immunologic response to gram-negative bacterial infections. Gram-negative bacteria contain LPS on their outer cell wall. Together with bactericidal permeability-increasing protein (BPI), LBP binds LPS and interacts with the CD14 receptor, probably playing a role in regulating LPS-dependent monocyte responses.

    LBP Reagents

    CKH113  Human LBP Multispecies Reactive ELISA Kit

    CKM043  Mouse LBP ELISA Kit

    CML002  Mouse Anti-Human LBP Clone biG 42 mAb†

    CML003  Mouse Anti-Human LBP Clone biG 48 mAb†

    CML004  Mouse Anti-Human LBP Clone biG 412 mAb*

    CML007  Mouse Anti-Human LBP Clone biG 43 mAb†

    CPC402A  Rabbit Anti-Human LBP pAb

    CML001  Mouse Anti-Mouse LBP Clone biG 33 mAb*

    CML005  Mouse Anti-Mouse LBP Clone biG 35 mAb†

    CPC105  Rabbit Anti-Mouse LBP pAb

    CRL701  Recombinant Human LBP

    CRL700  Recombinant Mouse LBP

    * Inhibits binding to CD14        † Does not inhibit binding to CD14

  • Prion Proteins Research Antibody

    Anti-prion antibody for use in research applications, clone 1E4:

    Sanquin Reagents, in cooperation with the research division of Sanquin, has developed a monoclonal anti-prion antibody for use in research applications: clone 1E4. The antibody is available form Cell Sciences in unconjugated form as well as biotin conjugated or HRP conjugated (see below).

    Item M1839: Anti-Prion, clone 1E4, Monoclonal Antibody
    Item M1840: Biotinylated Anti-Prion, clone 1E4, Monoclonal Antibody
    Item M1841: HRP Conjugated Anti-Prion, clone 1E4, Monoclonal Antibody

    Background Information
    The term “prion” was introduced by Stanley Prusiner in 1982 to describe the atypical infectious agent that causes transmissible spongiform encephalopathies, a group of infectious neurodegenerative diseases that include scrapie in sheep, Creutzfeldt-Jakob disease in humans, chronic wasting disease (CWD) in deer, and bovine spongiform encephalopathy (BSE) in cattle.

    The ‘mad cow’ crisis has drawn a lot of attention to prion diseases. Significant progress has been made in prion disease research, and many aspects of prion pathogenesis are now understood. And yet the diagnostic procedures available for prion diseases are not nearly as sensitive as they ought to be, i.e. a diagnostic test to proof the presence of pathogenic prion in blood or serum.

    Special Features of 1E4
    In contrast to many other anti-prion antibodies, mAb 1E4 has a broad species reactivity. This enables the detection of prion proteins in biological samples of many species including mouse adapted BSE (301V)-infected mice, scrapie-infected sheep, scrapie infected hamster (263K), CWD infected deer, sCJD- and vCJD-infected human on Western blots.

    Most of the currently available TSE tests are based on the fact that PrPC, normal prion protein, is digested by Protease K, whereas PrPSc, TSE specific prion, is relatively resistant to degradation by proteases. The special feature of mAb 1E4 is where the PrPSc epitope binds, PrP27-30, which is mostly hidden on non-digested prion proteins. After Proteinase K digestion the epitope becomes better available on proteinase resistant PrPSc, resulting in a significant signal increase. After digestion with Protease K , mAb 1E4 binds to PrPSc with a high affinity, whereas it has a low affinity for non-digested PrPSc. This makes mAb 1E4 a highly interesting antibody in current prion disease research.

    Applications
    1E4 has been tested in a broad variety of methods, such as Western blot, RIA, ELISA, EliBlot, FACS and immunohistochemistry. 1E4 allows prion research in many immunological techniques across a broad range of species.

    REFERENCE:
    Prusiner, S.B., Prions, Proc. Natl. Acad. Sci., Vol.95, pp 13363 - 13383, 1998.

     

  • Mouse MPO ELISA Kit

    Mouse MPO ELISA Kit
    1 x 96 tests
    Catalog Number CK210 Mouse MPO (Myeloperoxidase) ELISA kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of mouse MPO in plasma and cell culture supernatants. This assay employs an antibody specific for mouse MPO coated on a 96-well plate. Standards and samples are pipetted into the wells and MPO present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-mouse MPO antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of MPO bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.

    Included in the kit:

    • Microplate coated with Anti-Mouse MPO
    • Wash Buffer Concentrate (20x)
    • Recombinant Mouse MPO Standards
    • Assay Diluent C: Standard/Sample - Plasma Diluent Buffer
    • Assay Diluent B (5x): Standard/Sample - Cell Culture Medium Diluent
    • Detection Antibody: Anti-Mouse MPO Biotin
    • Streptavidin-HRP Concentrate (20,000x)
    • TMB One-Step Substrate Reagent (3, 3’, 5, 5’-tetramethylbenzidine in buffered solution)